Xu L-X, Yan Y, Zhang J-J, Zhang Y, Zhao M-H
Renal Division and Institute of Nephrology, Peking University First Hospital, Beijing, China.
Clin Exp Immunol. 2005 Dec;142(3):569-75. doi: 10.1111/j.1365-2249.2005.02949.x.
Recent evidence has suggested that IgA1-containing macromolecules and the glycosylation of IgA1 in sera from patients with IgAN might involve the pathogenesis of IgAN. However, whether the different histological phenotypes can be attributed or not to the aberrant glycosylation of macromolecular IgA1 has not yet been elucidated. The aim of the current study is to investigate the glycosylation of IgA1 molecules in serum IgA1-containing macromolecules and their association with pathological phenotypes of IgAN. Sera was collected from 40 patients with IgAN and 20 donors. Twenty patients had mild mesangial proliferative IgAN, the remaining 20 had focal proliferative sclerosing IgAN. Polyethylene glycol 6000 was used to precipitate the macromolecules from sera of patients and controls. Biotinylated lectins were used in an enzyme-linked immunosorbent assay (ELISA) to examine different glycans on IgA1 molecules. The alpha2,6 sialic acid was detected by elderberry bark lectin (SNA) and the exposure of terminal galactose (Gal) and N-acetylgalactosamine (GalNAc) were detected by Arachis hypogaea (PNA) and Vilsa villosa lectin (VVL), respectively. The IgA1 glycans levels corrected by IgA1 concentrations were compared between patients and controls. Reduced terminal alpha2,6 sialic acid of IgA1 (79.89 +/- 25.17 versus 62.12 +/- 24.50, P = 0.034) was demonstrated only in precipitates from sera of patients with focal proliferative sclerosing IgAN, compared with those from controls. Reduced galactosylation of IgA1 molecules in precipitates was demonstrated in patients with both mild mesangial proliferative IgAN and focal proliferative sclerosing IgAN compared with normal controls (24.52 +/- 18.71 versus 76.84 +/- 32.59 P = 0.000 and 33.48 +/- 25.36 versus 76.84 +/- 32.59 P = 0.000). However, no significant difference was found in IgA1 glycosylation in the supernatant between patients and normal controls (P > 0.05). The glycosylation deficiency of IgA1 existed only in serum IgA1-containing macromolecules of patients with IgAN, and was associated with the renal pathological phenotypes. This suggests that aberrant glycosylation of IgA1 in serum macromolecules might be a contributory factor in the pathogenesis of IgAN.
近期证据表明,IgA肾病(IgAN)患者血清中含IgA1的大分子及IgA1的糖基化可能参与了IgAN的发病机制。然而,不同的组织学表型是否可归因于大分子IgA1的异常糖基化尚未阐明。本研究的目的是调查血清中含IgA1的大分子中IgA1分子的糖基化情况及其与IgAN病理表型的关系。收集了40例IgAN患者和20例供体的血清。20例患者为轻度系膜增生性IgAN,其余20例为局灶增生性硬化性IgAN。用聚乙二醇6000从患者和对照的血清中沉淀大分子。在酶联免疫吸附测定(ELISA)中使用生物素化凝集素来检测IgA1分子上的不同聚糖。接骨木树皮凝集素(SNA)检测α2,6唾液酸,花生凝集素(PNA)和绒毛百脉根凝集素(VVL)分别检测末端半乳糖(Gal)和N-乙酰半乳糖胺(GalNAc)的暴露情况。比较患者和对照之间经IgA1浓度校正后的IgA1聚糖水平。与对照相比,仅在局灶增生性硬化性IgAN患者血清沉淀物中证实IgA1的末端α2,6唾液酸减少(79.89±25.17对62.12±24.50,P = 0.034)。与正常对照相比,轻度系膜增生性IgAN和局灶增生性硬化性IgAN患者沉淀物中IgA1分子的半乳糖基化均减少(24.52±1/span>18.71对76.84±32.59,P = 0.000;33.48±25.36对76.84±32.59,P = 0.000)。然而,患者和正常对照之间上清液中IgA1糖基化无显著差异(P>0.05)。IgA1的糖基化缺陷仅存在于IgAN患者含血清IgA1的大分子中,且与肾脏病理表型相关。这表明血清大分子中IgA1的异常糖基化可能是IgAN发病机制中的一个促成因素。